Tenet Healthcare (THC) Bank of America Global Healthcare Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Bank of America Global Healthcare Conference 2026 summary
13 May, 2026Utilization and volume trends
Q1 saw weak respiratory volumes in January but improved sequentially, ending above expectations in March.
Acute business outperformed, with new hospitals in Florida ramping up well.
Physician practices remain busy, indicating strong future hospital demand.
Utilization trends support confidence in meeting full-year guidance.
The company is more bullish on its annual outlook after Q1 performance.
Core growth and financial normalization
Q1 included normalization items like Conifer and Medicaid payments, largely offsetting each other.
HIX impact was about 10% down in Q1, better than the expected 20% for the year.
Hospital segment margins were strong at 17.5% in Q1.
Expense management flexed with volume, supporting confidence in annual guidance.
Growth strategies and capital allocation
Focus remains on high acuity business and expansion of related services.
Increased capital expenditure in hospitals post-transaction supports growth.
Expense reduction initiatives, including technology and AI, are being executed and will build over time.
Confident in achieving 10% core growth from 2025 to 2026.
Latest events from Tenet Healthcare
- Q2 2026 profit and margin growth drove higher FY 2026 guidance and a $2B buyback increase.THC
Q2 202625 Jul 2026 - High-acuity focus and disciplined capital deployment drive growth amid policy uncertainty.THC
Barclays 27th Annual Global Healthcare Conference9 Jul 2026 - Q4 and FY 2024 results show margin expansion, deleveraging, and robust ambulatory growth.THC
Q4 20249 Jul 2026 - Q2 2024 Adjusted EBITDA up 12% to $945M; FY 2024 guidance and buybacks increased.THC
Q2 20248 Jul 2026 - Q3 net income soared to $472M on asset sales, with EBITDA up 15% and FY guidance raised.THC
Q3 20248 Jul 2026 - Q1 2025 Adjusted EBITDA up 14%, margin gains, strong cash flow, and $348M in buybacks.THC
Q1 20258 Jul 2026 - Q1 2026 net income jumped 73% to $702M, with strong EBITDA and robust cash flow.THC
Q1 20269 May 2026 - 2025 performance exceeded targets, supporting high executive pay and strong shareholder returns.THC
Proxy filing16 Apr 2026 - Virtual meeting to elect 12 directors, approve pay, and ratify auditors, with board support.THC
Proxy filing16 Apr 2026